4/7
08:00 am
ikt
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Low
Report
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
4/3
02:10 pm
ikt
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/3
02:01 pm
ikt
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
04:01 pm
ikt
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Medium
Report
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
3/5
07:56 am
ikt
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Medium
Report
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
3/4
08:00 am
ikt
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
2/25
06:24 am
ikt
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
Medium
Report
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
1/24
05:08 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
09:00 am
ikt
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.